Suggested remit - To appraise the clinical and cost effectiveness of abemaciclib within its marketing authorisation for treating hormone-receptor positive, HER2-negative breast cancer.
Following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Process STA pre-2018
ID number 1347

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
03 September 2018 Suspended, Following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.
03 September 2018 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy. However, following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.
19 October 2017 - 16 November 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
01 October 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance